| Anti-Ku positive (n = 14) | Controls (n = 43) | Anti-Ku positive (%) | 95% CI of age/sex-matched controls (%) | |
| dcSSc | 2 | 12 | 14.3 | 14.3 to 42.9 |
| Teleangiectasias* | 5 | 28/42 | 35.7 | 53.8 to 92.3 |
| Raynaud phenomenon† | 12 | 43 | 85.7 | 100.0 |
| Ulcers* | 4 | 22/41 | 28.6 | 38.5 to 78.6 |
| Calcinosis | 3 | 8/39 | 21.4 | 15.4 to 50.0 |
| Acroosteolysis | 1 | 4/33 | 7.1 | 0.0 to 25.0 |
| Sicca symptoms | 4 | 10 | 28.6 | 7.1 to 42.9 |
| Synovitis* | 6 | 9 | 42.9 | 7.1 to 38.5 |
| Joint contractions* | 7 | 11 | 50.0 | 7.1 to 42.9 |
| Muscle weakness, atrophy* | 6 | 3 | 42.9 | 0.0 to 21.4 |
| CK elevation* | 6 | 1 | 42.9 | 0.0 to 7.1 |
| EMG† | 4/10 | 1/11 | 40.0 | 0.0 |
| Biopsy | 2/5 | 0/0 | 40.0 | NP |
| Peripheral neuropathy | 4 | 5/27 | 28.6 | 0.0 to 36.4 |
| Oesophageal (dysphagia, reflux) | 10 | 27 | 71.4 | 53.9 to 85.7 |
| Stomach (early satiety, vomiting) | 3 | 4 | 21.4 | 0.0 to 21.4 |
| Intestine | 2 | 4 | 14.3 | 0.0 to 30.8 |
| Dyspnoea (significant) | 5 | 21 | 35.7 | 35.7 to 64.3 |
| Fibrosis; plain x ray | 8 | 24 | 57.1 | 35.7 to 71.4 |
| Restrictive defect (lung function test) | 4/12 | 16/42 | 36.4 | 28.6 to 64.3 |
| Pulmonary hypertension (ECHO) | 5/11 | 10/38 | 45.5 | 21.4 to 53.8 |
| Palpitations | 1 | 3 | 7.1 | 7.1 to 21.4 |
| Conduction blocks | 3 | 7/42 | 21.4 | 14.3 to 35.7 |
| Diastolic function abnormal | 2/11 | 8/38 | 18.2 | 0.0 to 33.3 |
| Reduced ventricular ejection fraction | 1/11 | 4/38 | 9.1 | 0.0 to 16.7 |
| Hypertension* | 2 | 18 | 14.3 | 28.6 to 64.3 |
| Renal crisis† | 0 | 0 | 0.0 | 0.0 |
| ANA | 14 | 43 | 100.0 | 92.9 to 100.0 |
| ACA* | 0 | 15 | 0.0 | 21.4 to 57.1 |
| Nucleolar* | 12 | 11 | 85.7 | 21.4 to 57.1 |
| Punctuate nucleolar* | 1 | 4 | 7.1 | 14.3 to 42.9 |
| Anti-ENA | 3 | 13 | 21.4 | 14.3 to 50.0 |
| Anti-Scl70* | 1 | 9 | 7.1 | 14.3 to 50.0 |
| Other | 2 | 4 | 14.3 | 7.1 to 21.4 |
Biopsy and EMG were suggestive of myositis. Statistical calculations were performed from columns 4 and 5.
*Statistically significant; †no confidence intervals could be calculated since all controls had the same value.
ACA, anti-centromere antibodies; ANA, anti-nuclear antibodies; CK, creatine phosphokinase; dcSSc, diffuse cutaneous SSc; ECHO, echocardiography; EMG, electromyogram; ENA, extractable nuclear antigen; NP, biopsy not performed; Scl, scleroderma.